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Abstract 
This meeting report presents the outcomes of a workshop held in Bangkok on December 1st 2014, where the follow-
ing challenges were discussed: the threat of resistance to artemisinin and artemisinin-based combination therapy in 
the Greater Mekong Sub-region (GMS) and in Africa; access to treatment for most at risk and hard to reach popula-
tion; insecticide resistance, residual and outdoors transmission. The role of operational research and the interactions 
between research institutions, National Malaria Control Programmes, Civil Society Organizations, and of financial and 
technical partners to address those challenges and to accelerate translation of research into policies and programmes 
were debated. The threat and the emergency of the artemisinin resistance spread and independent emergence in the 
GMS was intensely debated as it is now close to the border of India. The need for key messages, based on scientific 
evidence and information available and disseminated without delay, was highlighted as crucial for an effective and 
urgent response.
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Background
Malaria situation worldwide
In over a decade, remarkable achievements in malaria 
control have been made. Malaria mortality rates have 
been reduced by 47% in all age groups worldwide, 
between 2000 and 2013, leading to an estimated 4.3 mil-
lion malaria deaths averted during the same period. A 
total of 64 countries that had on-going malaria transmis-
sion in 2000 are actually meeting the millennium devel-
opment goals (MDG) target of reversing the incidence of 
malaria, and 55 of these countries are on track to meet 
roll back malaria (RBM) and World Health Assembly tar-
gets of reducing malaria case incidence rates by 75% in 
2015 [1].
In the last decade, resistance to commonly used insec-
ticides and anti-malarial drugs has been emerging or 
expending and poses a major threat to the sustain-
ability of these progresses. Monitoring of the resistance 
trends at country level is crucial to properly quantify and 
address those threats. In the last few years, new chal-
lenges have emerged, further complicating the potential 
solutions to the issue of drug and of insecticide resistance 
and to attain the goal of elimination.
Objectives of the workshop
As a side event to the Roll Back Malaria Board Meeting, 
this 1  day workshop was organized by Expertise France 
(formerly known as France Expertise Internationale) in 
the framework of the 5% Initiative in Bangkok on Decem-
ber 1st 2014. This 5% Initiative is an indirect contribution 
from France to the Global Fund equivalent to 5% of the 
total French contribution to the Fund each year. It pro-
vides technical support to countries allocated Global 
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Fund grants in designing, implementing, monitoring/
evaluating and measuring the impact of programmes 
financed by the Global Fund in order to enhance their 
effectiveness and impact on health. The workshop con-
vened a global community of over 80 researchers, rep-
resentatives of National Malaria Control Programmes 
(NMCPs), of Civil Society Organizations (CSOs), and of 
financial and technical partners (list of participants as 
Additional file 1). The objectives of this workshop were:
  • To discuss the new challenges for malaria control and 
elimination.
  • To discuss the role of operational research for inno-
vation in designing interventions.
  • To share the results of projects supported by the 5% 
Initiative.
Meeting sessions
The workshop was organized in four main plenary ses-
sions. The first three sessions comprised presentations by 
malaria experts followed by discussions with all partici-
pants based on challenges identified:
  • Session 1: Resistance to artemisinin and ACT in the 
Greater Mekong Sub-Region and Africa: current and 
future approaches.
  • Session 2: Access to treatment for most at risk and 
hard to reach population and the need for evaluation 
of malaria interventions.
  • Session 3: Insecticide resistance, residual and out-
doors transmission: which new strategies and inter-
ventions to overcome these challenges?
The last session was an open debate among all partici-
pants on how to improve interactions between research 
institutions, NMCPs, CSOs and financial and technical 
partners to accelerate translation of research into policies 
and programmes.
Session 1: Resistance to artemisinin and ACT  
in the Greater Mekong Sub‑Region and Africa: 
current and future approaches
The emergence of resistance to anti-malarial drugs [chlo-
roquine (CQ), sulfadoxine-pyrimethamine (SP) and 
mefloquine (MQ)] occurred historically in western Cam-
bodia, at the border with Thailand. The resistance then 
spread westward to reach India in the 1970s and East 
Africa in the 1980s to then extend to the whole African 
continent by 1992 [2]. This situation led to millions of 
deaths [3, 4]. A video developed by WWARN [5] shows 
the spread of CQ and SP resistance from the Thai-Cam-
bodia border to the rest of the world between 1960 and 
2006. Anti-malarial drug resistance, as defined by WHO 
[6] was often documented decades after the events of 
emergence or spread, leading to a gap between the infor-
mation gathered by researchers and actions taken by pro-
gramme managers and implementers. When revisiting 
the history of CQ and SP resistance, it is clear that the 
response was slow (delay in changing drug regimen) and 
that there was an inadequate assessment of the risk and 
of the cost of resistance. The adoption and use of ACT 
led to the expectation that control and elimination of 
malaria could be achieved in a relatively shorter period 
of time. Unfortunately the emergence of artemisinin and 
insecticide resistance renders this optimistic scenario 
unlikely (See [7] for definition of artemisinin resist-
ance). The adoption of artemisinin derivatives in combi-
nation with a partner drug as first-line treatment and of 
artesunate in replacement of quinine for severe malaria 
reversed this situation for about a decade; until studies 
showed an increase of parasite clearance time in western 
Cambodia [8]. The Emergency Response to Artemisinin 
Resistance (ERAR) framework was released in April 2013 
[9] and followed by the establishment of the Resistance 
Artemisinin Initiative (RAI) and of the WHO ERAR 
regional hub supported by the Global Fund to fight AIDS, 
TB and Malaria (GFATM) and by the Bill and Melinda 
Gates Foundation (BMGF). A multi donor trust fund 
supported by the Asian Development Bank (ADB) was 
also recently established to support the response to this 
issue. Despite this, artemisinin resistance threatens to 
follow the same historical trajectory from Southeast Asia 
to the Indian subcontinent as seen in the past with other 
anti-malarial medicines and further spread or emerge in 
Africa [10]. In place where high resistance to artemisinin 
has been observed, failures to a conventional treatment 
regimen with ACT have been reported [11–16].
Nicholas White (Mahidol-Oxford Tropical Medi-
cine Research Unit, Thailand) reviewed the situation of 
anti-malarial drug resistance in South East Asia (SEA). 
The Tracking Resistance to Artemisinin Collabora-
tion (TRAC) study conducted in South-East Asia and 3 
countries in Africa, between May 2011 and April 2013, 
has documented slow parasite clearance time [7] in 
southern Vietnam, central Myanmar, western and north-
eastern Cambodia, northern, southern and western Thai-
land [17]. It is now clear that the artemisinin resistance 
spread or emerged de novo in other parts of the GMS, 
and that there are occurrences of multiple independent 
emergences of resistance [18]. The discovery of the kelch-
13 molecular marker associated with delayed parasite 
clearance time [19] (some mutations beyond the amino 
acid position 440 being strongly associated with slow 
parasite clearance) allowed to refine those results by con-
firming that resistance is now widespread in most of the 
mainland of South-East Asia, the western front being in 
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Myanmar [17]. In a recent report, resistance to the arte-
misinin has been reported within 25  km of the Indian 
border [10].
The kelch mutations associated with resistance have 
only been selected in this region, and there is no evidence 
for selection of those mutations in other parts of the 
world. The genetic background, allowing for these muta-
tions to emerge and to persist, is only present in the GMS, 
leading to believe that we could stop its spread. Transfec-
tion studies show that when inserting the mutant gene in 
a parasite, particularly of Asian origin, reduced suscep-
tibility to artemisinin is induced. But those parasites are 
not selected elsewhere, suggesting a multigenic basis for 
resistance. Although mutations beyond amino acid posi-
tion 440 are associated with resistance, it is not always 
the case as shown with the mutation in position 578 seen 
in different locations outside of SEA but not associated 
with artemisinin resistance.
François Nosten (Shoklo Malaria Research Unit, 
Thailand) discussed the challenges faced for malaria 
elimination in the GMS. Challenges for elimination of 
Plasmodium vivax were highlighted: hypnozoites and its 
large number of carriers; the often unrecognized sever-
ity and mortality of P. vivax infections; the emergence of 
P. vivax resistance to CQ; G6PD deficiency and the risk 
of haemolysis after treatment by primaquine; and sub-
microscopic infections. In line with those challenges, 
the aim of a project supported by the 5% Initiative in the 
GMS and involving other institutions (Institute Pasteur 
of Cambodia, Wellcome Trust units in Thailand, Laos 
and Vietnam) is to support national programmes to map 
genetic mutations causing G6PD deficiency as well as 
setting new assays to better detect gametocytes carriers.
In an on-going project supported by GFATM and 
BMGF, where 800 villages in Myanmar have been 
mapped and qPCR surveys conducted in 15 of them, 
preliminary results show that more than 40% of the 
population are asymptomatic carriers and about 80% of 
those with Plasmodium falciparum carry the k13 muta-
tions conferring resistance, probably contributing to the 
on-going transmission of those artemisinin resistant 
parasites. The speed of the spread of artemisinin resist-
ance westward in Myanmar is alarming: a retrospective 
analysis of blood samples collected on the Thai-Myanmar 
border since 2003 shows that the K13 molecular marker 
proportion in the population has increased. The num-
ber of cases has declined and as a result the proportion 
of K13 mutants has increased, but the high proportion 
(80%) of K13 mutants is also found in the sub-micro-
scopic reservoirs, hence the urgency to eliminate them as 
fast as possible, because the parasites that are now trans-
mitted are almost all resistant (Unpublished T. Anderson 
ASTMH 2014).
Preliminary results from studies (supported by BMGF 
and Wellcome Trust) conducted in villages at the Thai-
Myanmar border, as well as in Cambodia and Vietnam, 
show that following Mass Drug Administration (MDA) 
monthly for 3  months, elimination of asymptomatic 
carriers seem feasible in some villages after 18  months, 
although in other villages, malaria symptomatic and 
asymptomatic cases persist after 18 months. This differ-
ence in outcomes is likely due to low level of community 
participation and population movements. Following a 
question on the risk of increasing drug pressure on the 
parasite when using MDA, it was further clarified that as 
asymptomatic carriers have acquired some immunity and 
have very low parasitaemia, the probability of selection of 
resistance is very low.
Véronique Sinou (Aix-Marseille Université, France) 
presented the advantages of an ultramobile laboratory 
(K-LMP) for the surveillance of malaria in Democratic 
Republic of Congo (DRC). This project is supported by 
the 5% Initiative and involved several institutions (Aix-
Marseille University, France; Monkole Medical Centre, 
DRC; Centre de Formation et d’Appui Sanitaire, DRC; 
National Institute of Biomedical Research, DRC). This 
project aims to evaluate the susceptibility of P. falciparum 
clinical isolates to eight anti-malarial drugs by associating 
the ex vivo assay and the analysis of molecular markers of 
resistance, in the provinces of Bas-Congo and Kinshasa. 
The K-LMP is made of four compartmented boxes stack-
able by pairs. In its operational configuration, the boxes 
1 and 4 (88 × 64 × 100 cm; 0.45 m3) rest on the boxes 2 
and 3 (88 × 64 × 72 cm; 0.35 m3), respectively. These are 
easy to transport from one study site to another allow-
ing to bring closer to the patients the means necessary 
to the collection and processing of the samples, for the 
diagnosis, and to the achievement of ex vivo assays with 
the same quality as in reference laboratories, especially 
regarding the reproducibility of in  vitro culture param-
eters [20]. To do this, the boxes are equipped with a class 
II biological safety cabinet and an incubator adapted to 
field conditions, and a field suitable ELISA reader. This 
laboratory environment can be set up in 30 min without 
specific tools and does not need qualified technicians.
Preliminary results from ex vivo studies showed resist-
ance to chloroquine and reduced susceptibility to qui-
nine, as well as to mefloquine in the two provinces; 
isolates were susceptible to lumefantrine and pipe-
raquine. However, isolates from Bas Congo showed 
reduced susceptibility to amodiaquine (AQ), which could 
be explained by the proximity with Angola where a geno-
type (SVMNT on Pfcrt gene), which might be linked to 
AQ resistance, has been recently identified. Molecular 
marker analysis might help to identify if this genotype 
is present in this region of DRC. In addition, one isolate 
Page 4 of 11Guyant et al. Malar J  (2015) 14:279 
from Bas Congo presented a reduced susceptibility to 
dihydroartemisinin.
The finding of varying level of parasites susceptibility at 
two sites is not surprising in a large country such as RDC, 
but emphasizes the need for systems for the monitoring 
of parasite resistance so as to best adapt the treatments to 
the local realities. For this, training and capacity building 
of laboratory techniques and methodology are provided 
to partners in DRC with the aim to have the medical and 
laboratory staff to be autonomous for conducting field 
studies by this end of the project.
Philippe Guérin (WWARN) gave a presentation on: 
“Risk of anti-malarial drug resistance worldwide: are we 
ready?” The fact was emphasized that from an epidemi-
ological point of view, the current situation is an emer-
gence and an emergency, and that artemisinin resistance 
should be considered as such.
Intelligence and clinical trials The WWARN data 
centre on clinical assessments currently contains over 
110,000 individual patient data, representing more 
than 2/3 of all ACT published data, collected between 
1995 to date. Overall this represents a large number of 
studies, however when looking at the last decade, rela-
tively much less studies have been conducted, compared 
to the period 2000–2005 when a lot of attention was 
given at documenting CQ and SP resistance. Following 
the introduction of ACT at large scale, the attention of 
donors and researchers shifted to other issues and much 
less clinical trials have been conducted especially in 
Africa.
Intelligence and molecular markers A pooled analysis of 
studies conducted with artemether-lumefantrine showed 
that the presence of parasites carrying the pfmdr1 N86 
molecular marker is associated with a decrease of clini-
cal efficacy, mostly due to lumefantrine resistance; a simi-
lar association of parasites with the pfmdr1 86Y marker 
and poor response to amodiaquine has also been iden-
tified [21]. When artemisinin efficacy is compromised, 
the partner drugs in the ACT are then under very strong 
selection. Monitoring key molecular markers in pfmdr1 
and pfcrt markers could be used to predict lumefantrine 
or amodiaquine or mefloquine failure of the artemisinin-
based combinations that carry those partners. Since 
artemisinin resistance is widespread in the GMS, this sit-
uation is common, and has led already to very significant 
failure of DHA-piperaquine in Western Cambodia [14, 
16, 22, 23].
Similarly in the GMS, the proportion of parasites with a 
k13 mutant could be used to monitor parasites that clear 
slowly after artemisinin treatment [19]. In 2013–2014, 
blood samples were collected in about 50 sites in Myan-
mar, showing the extension of resistance up to the Indian 
border in the northern part of the country, and studies on 
the Myanmar/China border have also shown high levels 
of k13 mutant parasites with slow clearance [10, 24, 25].
Intelligence and anti-malarial quality Anti-malarial 
quality characteristics can be summarized as: falsified, 
substandard or degraded. These characteristics lead to 
sub-optimal drug exposure and subsequently to: death 
and disability, economic losses, loss of faith in health 
systems and drug resistance [26]. In order to understand 
the existing data, WWARN developed a comprehensive, 
open-access, global database that collates customized 
summaries of all published anti-malarial quality reports 
since 1946 [27]. No publicly available reports on the qual-
ity of anti-malarials are available for 60.6% (63) of the 
104 malaria-endemic countries. Of 9,348 anti-malarials 
sampled, 30.1% (2,813) failed chemical/packaging qual-
ity tests. Most reports of this review did not distinguish 
between falsified, sub-standard or degraded medicines.
A recent study [28] shows that, based on a simulation 
where 30% of artemisinin-based combinations failed and 
treatment to severe malaria had to revert to quinine, each 
year would experience an increase of more than 116,000 
deaths due to malaria, an excess of 32MUS$ in health 
care costs and more than 385MUS$ productivity loss due 
to extended patient illness. A lot of research is done, but 
more is needed to effectively translate research results 
into public health action by:
The main recommendations from session 1 were:
  • Given that the spread of artemisinin resistant para-
sites to India could be the first step in their spread 
to Africa; the current priority must be to address this 
problem in South-East Asia before it can become a 
problem in Africa. To avoid future malaria epidem-
ics in all areas, it is crucial to act now to eliminate 
artemisinin resistant parasites in the GMS before the 
ACT completely loses its efficacy.
  • Although P. falciparum elimination in the GMS is 
realistic, feasible and particularly urgent in the con-
text of drug resistance, the main challenges are to 
ensure community participation, to address residual 
vectorial capacity. Operational research is crucial to 
address those challenges innovatively.
  • Engaging political support and cooperation at all lev-
els, from donor institutions, governments, national 
programmes and the WHO is intensely needed. 
Without this comprehensive commitment elimina-
tion will not be possible.
  • Information must be gathered on the response of 
parasites where elimination is planned, and the anal-
ysis and proper interpretation must be provided to 
guide the appropriate action in each case. However, 
crucial intelligence gaps persist, and these must be 
filled urgently.
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  • Given the extreme risk to ACT efficacy currently 
seen in the GMS, preserving ACT potency as long 
as possible is a paramount priority. When new drugs 
are introduced, their dosing regimens and surveil-
lance for any signs of resistance must be planned 
before deployment and rigorously pursued to sustain 
their efficacy for as long as possible.
Session 2: Access to treatment for most at risk 
and hard to reach population and the need 
for evaluation of malaria interventions
Population movement and migration from areas of drug 
resistance contribute to the potential spread of drug 
resistant parasites, it also potentially contributes to rein-
troduction of the parasite in areas where the disease has 
been eliminated or is not anymore a public health prob-
lem. Due to their mobility patterns, the remoteness of 
their location or the illegal aspects of their activity, these 
mobile and migrant populations, are often hard to reach 
with current malaria tools and interventions [29–31].
Due to the ecology of vectors, malaria in SEA is a 
problem of the forest and, therefore, of border areas 
in this region. In this context, population at risk are 
people living in or close to the forest, local popula-
tion often ethnic minorities and mobile and migrant 
population looking for work or new patches of land. 
The main activities MMPs are involved in are: farming; 
employed work on plantations, on construction sites 
(dams, roads), mines; uniformed personnel (border 
control); forest products collection. Different groups 
with different activities have different level of malaria 
risk, mainly biological and socio-economic. The bio-
logical risk depends on the level of immunity, on tim-
ing, duration and frequency of interactions with the 
forest. The socio-economic risk depends on poverty 
and knowledge about malaria (prevention, recognition, 
treatment). Newcomers, coming from areas with no 
malaria, have low knowledge of malaria and therefore 
might not seek appropriate diagnosis and treatment. 
As they are new in a community they may have no 
knowledge of health services and may not be known by 
health services. In addition, some of them might not 
be willing to be reached in the case of illegal activities 
(logging).
Shunmay Yeung (London School of Hygiene and Tropi-
cal Medicine) presented on the issue of access to hard 
to reach and most at risk population, i.e. Mobile and 
Migrant Population (MMP), focusing on the situation in 
Cambodia. The MMP is heterogeneous and includes dif-
ferent groups with different activities and related risks, 
and, therefore, requiring different approaches for malaria 
control and elimination. In order to identify the most 
appropriate interventions and to define and quantify the 
malaria risk for distinct groups of MMP in Cambodia, a 
population movement framework (PMF) was developed 
to inform the National Strategy. The main challenges 
include: the difficulties to access the most mobile, high-
est risk populations, especially those in remote areas 
and engaged in illegal activities; the limitations of cur-
rent vector control interventions; and the quality of, and 
adherence to ACT and availability of artemisinin mono-
therapies in the private sector.
In order to address those challenges, some new initia-
tives have taken place in Cambodia in different strate-
gic areas: Behaviour change communication (BCC), for 
example billboards on roads between urban areas and 
forest areas and the use of taxi drivers as health commu-
nication agent; Prevention, for example the piloting of 
insecticide treated hammock nets (ITHN), impregnated 
clothing, personal and spatial repellents, and a “forest 
package”, including ITHN and repellent; Case Manage-
ment including the social marketing of RDTs and ACT 
through private providers and the expansion of the net-
work of village malaria workers (VMW) in static vil-
lages to mobile malaria workers (MMW) and plantation 
malaria workers (PMW); Cross-border check points, 
showing that a high proportion of K13 mutation carriers 
were observed at the Cambodia-Lao border; and Surveil-
lance including the piloting for MMWs and PMWs col-
lecting information on malaria among MMP and to try to 
track them down.
Most of these initiatives have been relatively small scale 
pilot projects with differences in objectives, description 
and measurement of outcomes making it difficult to make 
robust conclusions about which interventions should be 
scaled up and how. Further operational research would, 
therefore, be useful to document the risk of malaria in 
different types of MMP (as was recently done in a large 
survey of rubber plantations), and to explore different 
approaches (including community led approaches) tar-
geting the MMP ensuring careful documentation of the 
effectiveness of the interventions and lessons learnt in 
terms of feasibility for scale-up.
Arjen Dondorp (Mahidol-Oxford Tropical Medicine 
Research Unit) reviewed the GFATM RAI grant provid-
ing an overview of the current status of implementa-
tion. The RAI is a regional grant of 100 MUS$ allocated 
to five countries in the GMS (Cambodia, Vietnam, Lao 
PDR, Myanmar and Thailand), which aims to tackle the 
problem of P. falciparum artemisinin resistance. Myan-
mar with the highest malaria burden and most people at 
risk in the region is receiving the biggest part of the grant 
(40M$), 15 M$ are allocated for the inter-country com-
ponent (ICC) interventions, especially for border areas 
where hard to reach population might not be covered by 
national malaria programmes.
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The main oversight body of the RAI is the Regional 
Steering Committee (RSC), which is driven by perfor-
mance and impact. The RSC main responsibilities are: 
(1) ‘high-level’ oversight of RAI project implementation 
(2) taking collective responsibility for strategic direction, 
and (3) allocating and reallocating GFATM resources as 
needed and/or when new evidence becomes available. 
The RSC is composed of voting and non-voting members 
as well as observers ensuring a broad representation of all 
stakeholders.
The ICC has been developed by the RSC (with finan-
cial support and technical expertise from the 5% Ini-
tiative) with a focus on border population using a “3 M” 
approach: mapping of hotspots (Map); Eliminate malaria 
in hotspots (Mop) including establishment VHW net-
work and presumptive treatment of high risk population; 
Monitoring impact and document changes (Monitor). 
WHO Malaria Policy Advisory Committee (MPAC) 
has adopted an elimination agenda for the GMS, which 
should be then formalized into a WHO policy and 
national strategies.
Recommendations from an advisory report to MPAC 
on “Feasibility of Plasmodium falciparum elimination in 
the GMS: technical, operational and financial challenges” 
are already being used by the RSC for reprogramming of 
the year 2 of the RAI grant [32].
The WHO-ERAR hub has planned a number of activi-
ties focusing on MMP and border or cross border activi-
ties which should be funded through the RAI and will 
work closely with the GMS countries to formulate their 
elimination action plans and priorities.
Sébastien Boyer (Institut Pasteur, Madagascar) pre-
sented a multidisciplinary approach to evaluate the 
effectiveness of malaria interventions, the PALEVALUT 
project supported by the 5% Initiative [33]. He noted that 
numerous and various control methods are used in dif-
ferent countries and that usually more than one is being 
used in a given country. This overlap of interventions in 
space and time makes it difficult to identify a causal rela-
tionship when programme objectives or impact are not 
achieved.
The objective of the project is to define performance 
indicators (PI) related to simple questions of effectiveness 
of interventions: Is it working as expected? PI: protective 
effectiveness, bio-efficacy; is it carried out as expected? 
PI: Coverage, management; what hinders effectiveness? 
PI: Determinants; Do we get what we pay for? PI: Cost 
effectiveness.
A toolbox has been developed based on existing tools 
from various disciplines: epidemiology, socio-anthropol-
ogy, health economy, biology, entomology, parasitology. 
The use of this toolbox was presented: tools and meth-
odologies from each discipline were used and applied 
on a given population combining cross-sectional survey, 
household qualitative survey, case–control study, stake-
holders interview and entomological investigations. Per-
formance indicators and indicators of effectiveness were 
derived from those surveys in an integrated way.
As an illustration of this approach, preliminary results 
were presented on the effectiveness of IRS: the epide-
miological component showed, in a sample of 2046 
individuals, no association between IRS and Plasmo-
dium infection. It was observed, through household 
quantitative questionnaires, that in houses were IRS 
was conducted, ITNs use was lower, leading to think, in 
first analysis, that people felt protected by IRS and did 
not need ITNs. However, qualitative household inter-
views showed that people did not feel protected by IRS, 
and that IRS was perceived at reducing nuisance (fleas, 
cockroaches) but not at reducing mosquitoes or not 
aimed at malaria. Additionally, entomological investiga-
tions showed that only a few percents of households met 
WHO standards of persistence of insecticide activity 
after 3 months.
To ensure operability, the project is build in three 
phases of evaluation of the Standard Operating Pro-
cedures, each following an implementation phase in 
countries with different settings [two countries in 2014 
(Madagascar and Bénin) and three more countries in 
2015 (Côte d’Ivoire, Cameroon and Niger)]. The main 
objective is to see which tools can be standardized, the 
ultimate goal being to evaluate a given control method 
for less than 200.000US$ in 1 year.
The main recommendations from session 2 were:
  • Operational research and new ways of evaluation 
are needed for MMP interventions, as routine health 
information systems have limitations and might not 
allow to capture the information needed, and existing 
type of surveys might not be sufficient for monitoring 
interventions for MMP. Examples of new approaches 
used for surveying the MMP recently are: respond-
ent driven sampling, cross-border surveys, plantation 
surveys.
  • Focusing on MMP is a priority given that they are at 
high risk of malaria and contributes to the spread of 
artemisinin resistance, however, more operational 
research (OR) is needed on documenting the malaria 
risk among different types of MMP, innovative tools 
and interventions as well as designing implementa-
tion in a way that can be evaluated, lessons learned 
and programmes adapted in an ongoing process.
  • Addressing the issue of artemisinin resistance in the 
GMS requires a sense of urgency, a common spirit, 
good coordination, regionally adapted integrated 
strategies, impact evaluation and good surveillance, 
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collaboration between public and private sector, tar-
geting difficult to reach populations, targeting the 
asymptomatic reservoir, adequate funding, and per-
sistence till the end goal is reached.
  • Multi-disciplinary approaches should be further 
explored as the combination of methods used in syn-
ergy provides a better understanding of the determi-
nants of effectiveness of malaria interventions than 
each of this method alone.
Session 3: Insecticide resistance, residual 
and outdoor transmission: which new strategies 
and interventions to overcome these challenges?
Residual and outdoor transmission, falling out of reach 
of effective and sustainable prevention measures, par-
ticularly for mobile people, constitute another emerging 
challenge for which new tools and strategies are urgently 
needed, both in Africa and in Asia [34, 35]. Residual 
transmission is defined as the malaria transmission 
remaining when there is good coverage with effective 
LLINs or IRS interventions. However, given the noctur-
nal biting behaviour of malaria vectors, during the period 
before sleeping time or early in the morning, there is 
no protection from mosquito bites. In addition human 
behaviours, especially activities conducted outside dur-
ing night time, further limit protection [34]
Malaria vectors have heterogeneous behaviours (early 
biting or outdoor versus indoor biting) varying by spe-
cies, but not only, as some species may have a different 
biting behaviour depending on the geographical loca-
tion, all those variations illustrating behavioural plastic-
ity [36, 37]. Mosquito behaviours and population might 
be selected over the long term by interventions/vec-
tor control measures, leading to: (1) a shift of species, 
as documented in Kenya where increasing coverage of 
LLINs led to an increasing proportion of Anopheles ara-
biensis, replacing progressively Anopheles gambiae [38]; 
(2) a shift to early biting, as in Benin, where scale-up of 
LLINs to universal coverage and replacement of LLINs 
led to selection of early biting mosquitoes [39]; (3) a 
shift to outdoor and early biting, as in Solomon islands, 
where after use of IRS with DDT, the relative proportion 
of Anopheles farauti with outdoor and early biting behav-
iour has increased [40].
Mosquito resistance to at least one insecticide has been 
identified in at least 64 malaria-endemic countries world-
wide and it continues to rise in Africa, South East Asia 
and Latin America [41, 42]. A Global Plan for Insecticide 
Resistance Management (GPIRM) in malaria vectors has 
been developed by WHO and RBM in 2012 to contain 
this threat [43]. In SEA, most of information on IR comes 
from the MALVECASIA network set up between 2002 
and 2005. It was found that IR was present and that there 
were several foci of resistance: DDT resistance in Anoph-
eles dirus was suspected in Cambodia; resistance to pyre-
throid of Anopheles minimus in Vietnam; or of Anopheles 
epiroticus in southern Vietnam [44]. The kdr mutations, 
that confer resistance to pyrethroids and DDT were also 
found, in different vectors, including Anopheles sinensis 
[45]. According to WHO there were no reports of insec-
ticide resistance in Thailand and Lao PDR [46], however 
the question was whether there was no resistance at all or 
that resistance was not (or under) reported.
Marc Coosemans (Institute of Tropical Medicine, 
Antwerp) reviewed the current status on residual trans-
mission and the challenges it represents for malaria 
elimination. Whether the selection pressure on behav-
ioural traits will lead to behavioural resistance and lead 
to a rebound of residual transmission remains a question. 
However, the emergence and the selection of heritably 
altered behaviour traits would be very complex to dem-
onstrate. Regardless of whether this residual transmission 
is due to pre-existing behavioural resilience or behav-
ioural resistance, new vector tools need to be developed 
to address the gap not covered by LLIN or IRS interven-
tions [34, 35].
Various vector control initiatives to address residual 
transmission are currently in place including: the Grand 
Challenges of the BMGF supporting “New approaches 
for addressing outdoor/residual malaria transmission”; 
the Innovative Vector Control Consortium (IVCC) call 
for “Responding to the challenge of outdoor transmission 
of malaria”; the WHO Vector Control Advisory Group 
(VCAG) evaluating new paradigms and tools; the RBM 
Vector Control working Group (VCWG) working on 
how to address outdoor/residual malaria transmission. 
A guidance note was recently issued by WHO-GMP on 
“Control of residual parasite transmission” [47].
Some innovative tools to address residual transmission 
include: topical and spatial repellents, attractive baits and 
traps. Topical repellents are very effective against mos-
quito bites, and has been shown in Bolivia to offer per-
sonal protection against malaria [48]. High coverage of 
repellent use can significantly reduce man-vector contact 
and so the malaria transmission [49, 50]. However, recent 
studies in Cambodia, Lao [51] and Ethiopia [52] failed to 
demonstrate community protection when using topical 
repellent at large scale, mainly because of lack of compli-
ance to use repellent daily and consistently in early even-
ing or morning, even when acceptance of the product 
was high. People indeed like to use repellents as a com-
fort tool when facing high mosquito nuisance but not for 
daily use to prevent a disease. With incomplete coverage 
and compliance it is likely that mosquito diversion will 
occur from users to non-users. New paradigms such as 
spatial repellents, attract-and-killing baits and traps are 
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still in the process of evaluation to raise epidemiological 
evidence and the public health value of these approaches 
[53].
Vincent Corbel (Institut de Recherche pour le Dével-
oppement, IRD) reviewed the current status of insec-
ticide resistance (IR) globally and presented the 
MALVEC project currently implemented in the SEA 
region through the 5% Initiative. The growing threat of 
insecticide resistance for malaria control and elimina-
tion worldwide was emphasized. The MALVEC project 
was set up to evaluate IR levels, type and mechanisms 
in the Lao PDR and the Thai-Lao border through a col-
laboration between the Institut Pasteur in Lao PDR, 
the Center for Malarialogy, Parasitology and Entomol-
ogy in Lao PDR, IRD and Kasetsart University in Thai-
land. The main objectives of the project are Research, 
Training and Expertise with four main components: 
(1) evaluation of anopheles bionomics and distribution 
and their role in malaria transmission; (2) evaluation of 
the level, type and mechanisms of resistance to public 
health pesticides; (3) evaluation of the impact of envi-
ronmental determinants (agricultural/PH practices) on 
vector dynamics and resistance selection; (4) strength-
ening capacity of Lao partners in medical entomology. 
The project follows the recommendations of the GMAP 
which calls for member states to implement an active 
system of insecticide resistance monitoring in vectors 
in order to improve preventive strategies and the fight 
against malaria worldwide.
Preliminary surveys conducted in the Vientiane prov-
ince, Lao PDR (using both human landing catch and 
cow bait collection) show that among mosquitoes col-
lected during the rainy season (4,032 anopheles) and the 
dry season (3,132 anopheles) 6% (out of 22 species) and 
67% (out of 19 species) were primary vectors (Anopheles 
maculatus and An. minimus), respectively. WHO suscep-
tibility tests showed that most of anopheles species were 
still susceptible to pyrethroids but some species (An. 
maculatus, Anopheles philippinensis, Anopheles vagus) 
show incipient resistance to DDT, whereas An. vagus 
showed incipient resistance to pyrethroids. In Thailand, 
at the border with Lao PDR and Cambodia, among mos-
quitoes collected during the rainy season (3,775 anoph-
eles) and the dry season (378 anopheles), 1% (out of 13 
species) and 27% (out of 11 species) were primary vec-
tors, respectively WHO bioassays showed resistance 
in all sites in Anopheles peditaeniatus and resistance to 
permethrin was suspected in Anopheles barbirostris, a 
secondary malaria vector. Preliminary findings showed 
that IR was present in anopheles species among which 
secondary malaria vectors but not in primary vectors. 
To conclude, IR is present at low levels in the Lao PDR, 
but is likely to increase by migration from neighbouring 
countries where resistance has been detected [44] Resist-
ance in mosquitoes can spread to very long distance 
through migration [54]. More recently the kdr mutations 
has spread to all Africa mainly by migration events [55, 
56]. In contrast occurrence of de novo mutations is rare 
and does not represent the main cause of resistance dif-
fusion around the world. Resistance can also increase by 
selection considering the increasing use of insecticides in 
agriculture and public health (e.g. LLIN coverage).
The main recommendations from session 3 were:
  • Universal coverage with LLINs should remain a 
priority as it suppresses most of the malaria trans-
mission due to primary vectors that feed predomi-
nately on humans sleeping inside the houses. This 
has largely contributed to the achievements in the 
decline of malaria. However, recognizing the limits of 
IRS or LLINs there is an urgent need for additional 
vector control measures for personal and community 
protection, the latter meaning that non-users would 
have the benefit of the protection.
  • The magnitude of the residual transmission should 
be evaluated in every country, regarding both mos-
quito and human behaviours.
  • There is a need for industry and academic partners to 
develop new vector control methods and paradigms 
for outdoor and residual transmission.
  • Regular monitoring of insecticide resistance should 
be continued in order to prevent further occurrence/
development of resistance in malaria vectors in the 
greater Mekong region. Data should be made avail-
able to member states and WHO as part of regional 
plan for insecticide resistance management.
The final session was an open debate on How to 
improve interactions between research institutions, 
national malaria control programmes and the donor 
community to accelerate translation of research into poli-
cies and programmes?
The debate was structured around three main interre-
lated topics and the main recommendations are summa-
rized below.
Current and potential future approaches to improve 
interactions between the research community 
and national programmes and donors
  • Data should be shared as early as possible to allow 
NMCP to use findings to adjust their national strate-
gies.
  • In the future, research design and strategy might 
need to be adapted from its classical approach, in 
collaboration with implementers, to be closer to a 
Page 9 of 11Guyant et al. Malar J  (2015) 14:279 
“learning by doing” approach to ensure timely data 
sharing and strategy adjustment.
  • Better coordination between stakeholders (country 
national programmes, researchers, donors) is needed 
in order to set up clear priorities at country level.
Governance structure and strategy needed to address  
the threat of artemisinin resistance
  • More involvement of heads of government is essen-
tial to engage in the multi-sectoral approach needed, 
including non-health ministries.
  • India and Bangladesh should be invited to join the 
RAI oversight committee as observers, similar to 
China’s position at the moment. The need to find 
ways to include and engage African countries in this 
process was as well highlighted.
  • Existing structures, like the RAI and RSC should be 
used and reinforced and the next East Asia summit 
of heads of states should be used to convey the emer-
gency for deeper commitment and to propose a budg-
eted plan to address artemisinin resistance in the next 
few years, in the broader context of the 2030 target.
Better communication and advocacy needed for better 
translation of research into policies
  • Based on scientific evidence and information avail-
able, simple and clear key messages should be 
“packaged”, expressing a common position, a com-
mon voice, from the scientific community. It should 
address the problem, the needs, the priority actions, 
a budgeted plan and the risks of “doing something 
versus doing nothing”.
  • Key messages should be disseminated to a broader, 
non-scientific audience, including grass root com-
munities exposed to and affected by malaria, national 
malaria control programmes, donors and interna-
tional institutions and importantly policy makers and 
governments.
Conclusions
This meeting report present the outcomes of a 1-day 
workshop which convened a global community of over 
80 researchers, representatives of NMCPs, of CSOs, and 
of financial and technical partners. More operational 
research and adapted evaluation methods are needed to 
better address challenges for malaria control and elimi-
nation and will require innovation. Those challenges 
include: ensuring adequate community participation for 
new strategies, i.e. MDA and preventions methods for 
residual and outdoors transmission; closing intelligence 
gaps regarding surveillance of drug and insecticide resist-
ance, anti-malarial medicine quality; building capacity 
to better monitor insecticide resistance and mosquito 
behavioural changes linked to scale-up of vector control 
interventions.
The threat and the emergency of the artemisinin resist-
ance spread and independent emergence in the GMS 
was intensely debated as it is now close to the border 
of India. The need for key messages, based on scientific 
evidence and information available and disseminated 
without delay, was highlighted as crucial for an effective 
and urgent response. Those messages should be dissemi-
nated to broader, non-scientific audience, including grass 
root communities exposed to and affected by malaria, 
NMCPs, donors and international institutions and 
importantly policy makers and governments.
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